



CIRCULATING LEVELS OF PROLACTIN IN HUMAN





no patient was receiving phenothiazines, the patients with breast cancer does not L-DOPA, inhibitors of monoamine oxidase differ from that of the normal control or other drugs known to affect the secretion group. It is interesting to note that





	=	CIRCULATING LEVELS OF PROLACTIN IN HUMAN BREAST CANCER 16	5
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signi- serum and 43 + 5 ng respectively in the ficant role in mammary tumorisenesis.		i i	
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.		in the luteal phase of the cycle, is higher prolactin in cancer and non-cancer pa	l -
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.	<u> </u>		
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.	-		
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.	.—		
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.	F.		
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.	, .	<u> </u>	
range and mean value being 18-60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18–60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.	•		
range and mean value being 18–60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18–60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18–60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18–60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18–60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
range and mean value being 18–60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.	Ā		
range and mean value being 18–60 ng/ml a conclusion that prolactin has no signiserum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
serum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.			
serum and 43 + 5 ng respectively in the ficant role in mammary tumorigenesis.		•,	
		range and mean value being 18-60 ng/ml a conclusion that prolactin has no sign	i <u>-</u>
		serum and 43 ± 5 ng respectively in the ficant role in mammary tumorigenesi	S
Exercises to the second of the	A		
Exercises to the second of the			
A TA		<u> </u>	
^ <u></u>		à m	
	٠. ا		

Enhanced by Hypophysectomy. Nature. Lond.. Human Metastasizing Breast Cancer to the Treatment with 2-Br-ergocryptine (CB-154). In *Human Prolactin*. Eds J. L. Pasteels, C. 248, 525, MITTRA, I., HAYWARD, J. L. & MCNEILLY, A. S. (1974) Hypothalamic-pituitary-prolactin Axis in Robyn and F. J. G. Ebling. Amsterdam: Breast Cancer. Lancet. i. 889. Excerpta Medica. New York: American Elsevier Publ. Co. Inc. p. 268. SHETH. N. A., RANADIVE, K. J. & SHETH, A. R. MURRAY, R. M. L., MOZAFFARIAN, G. & PEARSON, O. H. (1972) Prolactin Levels with L-DOPA Treatment in Metastatic Breast Carcinoma. (1974) In vitro Binding of Radioiodinated Human In Prolactin and Carcinogenesis. Eds A. R. Bovns Placentral Lactogen to Murine Mammary Gland. and K. Griffiths. Cardiff; Alpha Omega Alpha. Eur. J. Cancer. 10, 653.

MURRAY, R. M. L. & SARFATY, G. (1974) Prolactin in Early and Advanced Breast Carcinoma. Quoted from E. del Pozo & E. Fluckiger, Prolactin Inhibition: Experimental and Clinical

Abstract in XI Internat. Cancer Congr., Florence, Studies. In Human Prolactin. Eds J. L.